nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—HTR7—vas deferens—urinary bladder cancer	0.107	0.413	CbGeAlD
Lurasidone—HTR2A—urine—urinary bladder cancer	0.0166	0.064	CbGeAlD
Lurasidone—CYP3A4—urine—urinary bladder cancer	0.0153	0.0593	CbGeAlD
Lurasidone—ADRA2C—prostate gland—urinary bladder cancer	0.00876	0.0339	CbGeAlD
Lurasidone—ADRA2C—seminal vesicle—urinary bladder cancer	0.00741	0.0287	CbGeAlD
Lurasidone—HTR7—epithelium—urinary bladder cancer	0.00701	0.0271	CbGeAlD
Lurasidone—ADRA2A—prostate gland—urinary bladder cancer	0.00699	0.027	CbGeAlD
Lurasidone—HTR1A—renal system—urinary bladder cancer	0.0068	0.0263	CbGeAlD
Lurasidone—HTR7—smooth muscle tissue—urinary bladder cancer	0.00675	0.0261	CbGeAlD
Lurasidone—HTR7—renal system—urinary bladder cancer	0.0065	0.0251	CbGeAlD
Lurasidone—ADRA2C—renal system—urinary bladder cancer	0.00597	0.0231	CbGeAlD
Lurasidone—ADRA2A—seminal vesicle—urinary bladder cancer	0.00591	0.0229	CbGeAlD
Lurasidone—ADRA2C—urethra—urinary bladder cancer	0.00587	0.0227	CbGeAlD
Lurasidone—HTR7—female reproductive system—urinary bladder cancer	0.0052	0.0201	CbGeAlD
Lurasidone—ADRA2A—urethra—urinary bladder cancer	0.00468	0.0181	CbGeAlD
Lurasidone—HTR2A—epithelium—urinary bladder cancer	0.00437	0.0169	CbGeAlD
Lurasidone—ADRA2C—vagina—urinary bladder cancer	0.00433	0.0167	CbGeAlD
Lurasidone—HTR2A—smooth muscle tissue—urinary bladder cancer	0.00421	0.0163	CbGeAlD
Lurasidone—HTR2A—renal system—urinary bladder cancer	0.00405	0.0157	CbGeAlD
Lurasidone—ADRA2A—female reproductive system—urinary bladder cancer	0.00382	0.0148	CbGeAlD
Lurasidone—CYP3A4—renal system—urinary bladder cancer	0.00375	0.0145	CbGeAlD
Lurasidone—ADRA2A—vagina—urinary bladder cancer	0.00345	0.0133	CbGeAlD
Lurasidone—HTR2A—female reproductive system—urinary bladder cancer	0.00325	0.0125	CbGeAlD
Lurasidone—CYP3A4—female reproductive system—urinary bladder cancer	0.003	0.0116	CbGeAlD
Lurasidone—HTR2A—vagina—urinary bladder cancer	0.00294	0.0113	CbGeAlD
Lurasidone—ADRA2C—lymph node—urinary bladder cancer	0.0028	0.0108	CbGeAlD
Lurasidone—ADRA2A—lymph node—urinary bladder cancer	0.00223	0.00863	CbGeAlD
Lurasidone—Somnolence—Fluorouracil—urinary bladder cancer	0.0011	0.00149	CcSEcCtD
Lurasidone—Hypotension—Cisplatin—urinary bladder cancer	0.0011	0.00148	CcSEcCtD
Lurasidone—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.0011	0.00148	CcSEcCtD
Lurasidone—Decreased appetite—Gemcitabine—urinary bladder cancer	0.0011	0.00148	CcSEcCtD
Lurasidone—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00109	0.00147	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00109	0.00147	CcSEcCtD
Lurasidone—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.00109	0.00147	CcSEcCtD
Lurasidone—Fatigue—Gemcitabine—urinary bladder cancer	0.00109	0.00147	CcSEcCtD
Lurasidone—Gastritis—Epirubicin—urinary bladder cancer	0.00109	0.00147	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.00108	0.00146	CcSEcCtD
Lurasidone—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00108	0.00146	CcSEcCtD
Lurasidone—Asthenia—Thiotepa—urinary bladder cancer	0.00108	0.00145	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00107	0.00145	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00107	0.00145	CcSEcCtD
Lurasidone—Infection—Etoposide—urinary bladder cancer	0.00107	0.00144	CcSEcCtD
Lurasidone—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.00107	0.00144	CcSEcCtD
Lurasidone—Dysphagia—Epirubicin—urinary bladder cancer	0.00106	0.00143	CcSEcCtD
Lurasidone—Influenza—Epirubicin—urinary bladder cancer	0.00106	0.00143	CcSEcCtD
Lurasidone—Dysuria—Methotrexate—urinary bladder cancer	0.00106	0.00143	CcSEcCtD
Lurasidone—Neutropenia—Methotrexate—urinary bladder cancer	0.00106	0.00143	CcSEcCtD
Lurasidone—Pruritus—Thiotepa—urinary bladder cancer	0.00106	0.00143	CcSEcCtD
Lurasidone—Tachycardia—Etoposide—urinary bladder cancer	0.00105	0.00142	CcSEcCtD
Lurasidone—Eosinophilia—Epirubicin—urinary bladder cancer	0.00105	0.00142	CcSEcCtD
Lurasidone—Dyspnoea—Cisplatin—urinary bladder cancer	0.00105	0.00142	CcSEcCtD
Lurasidone—Skin disorder—Etoposide—urinary bladder cancer	0.00105	0.00141	CcSEcCtD
Lurasidone—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.00105	0.00141	CcSEcCtD
Lurasidone—Hyperhidrosis—Etoposide—urinary bladder cancer	0.00104	0.00141	CcSEcCtD
Lurasidone—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.00104	0.0014	CcSEcCtD
Lurasidone—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.00104	0.0014	CcSEcCtD
Lurasidone—Angina pectoris—Epirubicin—urinary bladder cancer	0.00104	0.0014	CcSEcCtD
Lurasidone—Breast disorder—Doxorubicin—urinary bladder cancer	0.00103	0.00139	CcSEcCtD
Lurasidone—Diarrhoea—Thiotepa—urinary bladder cancer	0.00103	0.00139	CcSEcCtD
Lurasidone—Decreased appetite—Cisplatin—urinary bladder cancer	0.00102	0.00138	CcSEcCtD
Lurasidone—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.00102	0.00137	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00102	0.00137	CcSEcCtD
Lurasidone—Infestation NOS—Methotrexate—urinary bladder cancer	0.00101	0.00137	CcSEcCtD
Lurasidone—Infestation—Methotrexate—urinary bladder cancer	0.00101	0.00137	CcSEcCtD
Lurasidone—Hypotension—Etoposide—urinary bladder cancer	0.00101	0.00136	CcSEcCtD
Lurasidone—Gastritis—Doxorubicin—urinary bladder cancer	0.00101	0.00136	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.001	0.00135	CcSEcCtD
Lurasidone—Renal failure—Methotrexate—urinary bladder cancer	0.000995	0.00134	CcSEcCtD
Lurasidone—Dysuria—Epirubicin—urinary bladder cancer	0.000994	0.00134	CcSEcCtD
Lurasidone—Neutropenia—Epirubicin—urinary bladder cancer	0.000994	0.00134	CcSEcCtD
Lurasidone—Dizziness—Thiotepa—urinary bladder cancer	0.000992	0.00134	CcSEcCtD
Lurasidone—Influenza—Doxorubicin—urinary bladder cancer	0.000983	0.00133	CcSEcCtD
Lurasidone—Dysphagia—Doxorubicin—urinary bladder cancer	0.000983	0.00133	CcSEcCtD
Lurasidone—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000973	0.00131	CcSEcCtD
Lurasidone—Weight increased—Epirubicin—urinary bladder cancer	0.000967	0.0013	CcSEcCtD
Lurasidone—Dyspnoea—Etoposide—urinary bladder cancer	0.000961	0.0013	CcSEcCtD
Lurasidone—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000959	0.00129	CcSEcCtD
Lurasidone—Somnolence—Etoposide—urinary bladder cancer	0.000958	0.00129	CcSEcCtD
Lurasidone—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000958	0.00129	CcSEcCtD
Lurasidone—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000958	0.00129	CcSEcCtD
Lurasidone—Vomiting—Thiotepa—urinary bladder cancer	0.000954	0.00129	CcSEcCtD
Lurasidone—Infestation—Epirubicin—urinary bladder cancer	0.000947	0.00128	CcSEcCtD
Lurasidone—Infestation NOS—Epirubicin—urinary bladder cancer	0.000947	0.00128	CcSEcCtD
Lurasidone—Rash—Thiotepa—urinary bladder cancer	0.000946	0.00128	CcSEcCtD
Lurasidone—Dermatitis—Thiotepa—urinary bladder cancer	0.000945	0.00128	CcSEcCtD
Lurasidone—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000945	0.00127	CcSEcCtD
Lurasidone—Decreased appetite—Etoposide—urinary bladder cancer	0.000937	0.00126	CcSEcCtD
Lurasidone—Renal failure—Epirubicin—urinary bladder cancer	0.000931	0.00126	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000931	0.00126	CcSEcCtD
Lurasidone—Fatigue—Etoposide—urinary bladder cancer	0.000929	0.00125	CcSEcCtD
Lurasidone—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000921	0.00124	CcSEcCtD
Lurasidone—Dysuria—Doxorubicin—urinary bladder cancer	0.000919	0.00124	CcSEcCtD
Lurasidone—Neutropenia—Doxorubicin—urinary bladder cancer	0.000919	0.00124	CcSEcCtD
Lurasidone—Asthenia—Gemcitabine—urinary bladder cancer	0.000906	0.00122	CcSEcCtD
Lurasidone—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000898	0.00121	CcSEcCtD
Lurasidone—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000896	0.00121	CcSEcCtD
Lurasidone—Weight increased—Doxorubicin—urinary bladder cancer	0.000895	0.00121	CcSEcCtD
Lurasidone—Pruritus—Gemcitabine—urinary bladder cancer	0.000893	0.0012	CcSEcCtD
Lurasidone—Nausea—Thiotepa—urinary bladder cancer	0.000891	0.0012	CcSEcCtD
Lurasidone—Urethral disorder—Methotrexate—urinary bladder cancer	0.000891	0.0012	CcSEcCtD
Lurasidone—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000887	0.0012	CcSEcCtD
Lurasidone—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000884	0.00119	CcSEcCtD
Lurasidone—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000882	0.00119	CcSEcCtD
Lurasidone—Pruritus—Fluorouracil—urinary bladder cancer	0.000878	0.00118	CcSEcCtD
Lurasidone—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000877	0.00118	CcSEcCtD
Lurasidone—Infestation—Doxorubicin—urinary bladder cancer	0.000877	0.00118	CcSEcCtD
Lurasidone—Bradycardia—Epirubicin—urinary bladder cancer	0.000866	0.00117	CcSEcCtD
Lurasidone—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000864	0.00117	CcSEcCtD
Lurasidone—Renal failure—Doxorubicin—urinary bladder cancer	0.000862	0.00116	CcSEcCtD
Lurasidone—Abdominal pain—Etoposide—urinary bladder cancer	0.000852	0.00115	CcSEcCtD
Lurasidone—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000852	0.00115	CcSEcCtD
Lurasidone—Eye disorder—Methotrexate—urinary bladder cancer	0.000849	0.00115	CcSEcCtD
Lurasidone—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000849	0.00115	CcSEcCtD
Lurasidone—Asthenia—Cisplatin—urinary bladder cancer	0.000844	0.00114	CcSEcCtD
Lurasidone—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000843	0.00114	CcSEcCtD
Lurasidone—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.00084	0.00113	CcSEcCtD
Lurasidone—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000836	0.00113	CcSEcCtD
Lurasidone—Urethral disorder—Epirubicin—urinary bladder cancer	0.000834	0.00112	CcSEcCtD
Lurasidone—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000829	0.00112	CcSEcCtD
Lurasidone—Angiopathy—Methotrexate—urinary bladder cancer	0.000825	0.00111	CcSEcCtD
Lurasidone—Dizziness—Fluorouracil—urinary bladder cancer	0.000821	0.00111	CcSEcCtD
Lurasidone—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000818	0.0011	CcSEcCtD
Lurasidone—Diarrhoea—Cisplatin—urinary bladder cancer	0.000805	0.00109	CcSEcCtD
Lurasidone—Vomiting—Gemcitabine—urinary bladder cancer	0.000803	0.00108	CcSEcCtD
Lurasidone—Bradycardia—Doxorubicin—urinary bladder cancer	0.000801	0.00108	CcSEcCtD
Lurasidone—Mental disorder—Methotrexate—urinary bladder cancer	0.000796	0.00107	CcSEcCtD
Lurasidone—Rash—Gemcitabine—urinary bladder cancer	0.000796	0.00107	CcSEcCtD
Lurasidone—Dermatitis—Gemcitabine—urinary bladder cancer	0.000795	0.00107	CcSEcCtD
Lurasidone—Eye disorder—Epirubicin—urinary bladder cancer	0.000795	0.00107	CcSEcCtD
Lurasidone—Malnutrition—Methotrexate—urinary bladder cancer	0.000791	0.00107	CcSEcCtD
Lurasidone—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000789	0.00106	CcSEcCtD
Lurasidone—Vomiting—Fluorouracil—urinary bladder cancer	0.000789	0.00106	CcSEcCtD
Lurasidone—Rash—Fluorouracil—urinary bladder cancer	0.000783	0.00106	CcSEcCtD
Lurasidone—Dermatitis—Fluorouracil—urinary bladder cancer	0.000782	0.00105	CcSEcCtD
Lurasidone—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000777	0.00105	CcSEcCtD
Lurasidone—Asthenia—Etoposide—urinary bladder cancer	0.000773	0.00104	CcSEcCtD
Lurasidone—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000773	0.00104	CcSEcCtD
Lurasidone—Angiopathy—Epirubicin—urinary bladder cancer	0.000772	0.00104	CcSEcCtD
Lurasidone—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000771	0.00104	CcSEcCtD
Lurasidone—Back pain—Methotrexate—urinary bladder cancer	0.000765	0.00103	CcSEcCtD
Lurasidone—Pruritus—Etoposide—urinary bladder cancer	0.000763	0.00103	CcSEcCtD
Lurasidone—Arrhythmia—Epirubicin—urinary bladder cancer	0.00076	0.00102	CcSEcCtD
Lurasidone—Nausea—Gemcitabine—urinary bladder cancer	0.00075	0.00101	CcSEcCtD
Lurasidone—Vomiting—Cisplatin—urinary bladder cancer	0.000748	0.00101	CcSEcCtD
Lurasidone—Vision blurred—Methotrexate—urinary bladder cancer	0.000746	0.00101	CcSEcCtD
Lurasidone—Mental disorder—Epirubicin—urinary bladder cancer	0.000745	0.00101	CcSEcCtD
Lurasidone—Rash—Cisplatin—urinary bladder cancer	0.000742	0.001	CcSEcCtD
Lurasidone—Dermatitis—Cisplatin—urinary bladder cancer	0.000741	0.001	CcSEcCtD
Lurasidone—Malnutrition—Epirubicin—urinary bladder cancer	0.00074	0.000999	CcSEcCtD
Lurasidone—Diarrhoea—Etoposide—urinary bladder cancer	0.000738	0.000995	CcSEcCtD
Lurasidone—Nausea—Fluorouracil—urinary bladder cancer	0.000737	0.000995	CcSEcCtD
Lurasidone—Eye disorder—Doxorubicin—urinary bladder cancer	0.000735	0.000992	CcSEcCtD
Lurasidone—Anaemia—Methotrexate—urinary bladder cancer	0.000731	0.000986	CcSEcCtD
Lurasidone—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.00073	0.000985	CcSEcCtD
Lurasidone—Flatulence—Epirubicin—urinary bladder cancer	0.00073	0.000984	CcSEcCtD
Lurasidone—Back pain—Epirubicin—urinary bladder cancer	0.000716	0.000966	CcSEcCtD
Lurasidone—Angiopathy—Doxorubicin—urinary bladder cancer	0.000714	0.000963	CcSEcCtD
Lurasidone—Malaise—Methotrexate—urinary bladder cancer	0.000713	0.000962	CcSEcCtD
Lurasidone—Dizziness—Etoposide—urinary bladder cancer	0.000713	0.000962	CcSEcCtD
Lurasidone—Muscle spasms—Epirubicin—urinary bladder cancer	0.000712	0.00096	CcSEcCtD
Lurasidone—Vertigo—Methotrexate—urinary bladder cancer	0.000711	0.000959	CcSEcCtD
Lurasidone—Leukopenia—Methotrexate—urinary bladder cancer	0.000708	0.000955	CcSEcCtD
Lurasidone—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000703	0.000948	CcSEcCtD
Lurasidone—Nausea—Cisplatin—urinary bladder cancer	0.000699	0.000943	CcSEcCtD
Lurasidone—Vision blurred—Epirubicin—urinary bladder cancer	0.000698	0.000941	CcSEcCtD
Lurasidone—Mental disorder—Doxorubicin—urinary bladder cancer	0.000689	0.00093	CcSEcCtD
Lurasidone—Convulsion—Methotrexate—urinary bladder cancer	0.000685	0.000925	CcSEcCtD
Lurasidone—Vomiting—Etoposide—urinary bladder cancer	0.000685	0.000925	CcSEcCtD
Lurasidone—Malnutrition—Doxorubicin—urinary bladder cancer	0.000685	0.000924	CcSEcCtD
Lurasidone—Anaemia—Epirubicin—urinary bladder cancer	0.000684	0.000923	CcSEcCtD
Lurasidone—Agitation—Epirubicin—urinary bladder cancer	0.00068	0.000918	CcSEcCtD
Lurasidone—Rash—Etoposide—urinary bladder cancer	0.00068	0.000917	CcSEcCtD
Lurasidone—Dermatitis—Etoposide—urinary bladder cancer	0.000679	0.000916	CcSEcCtD
Lurasidone—Flatulence—Doxorubicin—urinary bladder cancer	0.000675	0.000911	CcSEcCtD
Lurasidone—Myalgia—Methotrexate—urinary bladder cancer	0.000674	0.000909	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000669	0.000902	CcSEcCtD
Lurasidone—Malaise—Epirubicin—urinary bladder cancer	0.000668	0.000901	CcSEcCtD
Lurasidone—Vertigo—Epirubicin—urinary bladder cancer	0.000665	0.000897	CcSEcCtD
Lurasidone—Syncope—Epirubicin—urinary bladder cancer	0.000664	0.000896	CcSEcCtD
Lurasidone—Leukopenia—Epirubicin—urinary bladder cancer	0.000663	0.000894	CcSEcCtD
Lurasidone—Back pain—Doxorubicin—urinary bladder cancer	0.000663	0.000894	CcSEcCtD
Lurasidone—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000659	0.000888	CcSEcCtD
Lurasidone—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000651	0.000878	CcSEcCtD
Lurasidone—Vision blurred—Doxorubicin—urinary bladder cancer	0.000646	0.000871	CcSEcCtD
Lurasidone—Convulsion—Epirubicin—urinary bladder cancer	0.000642	0.000865	CcSEcCtD
Lurasidone—Infection—Methotrexate—urinary bladder cancer	0.000641	0.000865	CcSEcCtD
Lurasidone—Nausea—Etoposide—urinary bladder cancer	0.00064	0.000864	CcSEcCtD
Lurasidone—Hypertension—Epirubicin—urinary bladder cancer	0.000639	0.000862	CcSEcCtD
Lurasidone—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000633	0.000854	CcSEcCtD
Lurasidone—Anaemia—Doxorubicin—urinary bladder cancer	0.000633	0.000854	CcSEcCtD
Lurasidone—Myalgia—Epirubicin—urinary bladder cancer	0.00063	0.00085	CcSEcCtD
Lurasidone—Agitation—Doxorubicin—urinary bladder cancer	0.00063	0.000849	CcSEcCtD
Lurasidone—Anxiety—Epirubicin—urinary bladder cancer	0.000628	0.000847	CcSEcCtD
Lurasidone—Skin disorder—Methotrexate—urinary bladder cancer	0.000627	0.000846	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000626	0.000844	CcSEcCtD
Lurasidone—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000624	0.000842	CcSEcCtD
Lurasidone—Malaise—Doxorubicin—urinary bladder cancer	0.000618	0.000833	CcSEcCtD
Lurasidone—Dry mouth—Epirubicin—urinary bladder cancer	0.000616	0.000832	CcSEcCtD
Lurasidone—Vertigo—Doxorubicin—urinary bladder cancer	0.000616	0.00083	CcSEcCtD
Lurasidone—Syncope—Doxorubicin—urinary bladder cancer	0.000614	0.000829	CcSEcCtD
Lurasidone—Leukopenia—Doxorubicin—urinary bladder cancer	0.000613	0.000827	CcSEcCtD
Lurasidone—Hypotension—Methotrexate—urinary bladder cancer	0.000603	0.000814	CcSEcCtD
Lurasidone—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000602	0.000812	CcSEcCtD
Lurasidone—Infection—Epirubicin—urinary bladder cancer	0.0006	0.00081	CcSEcCtD
Lurasidone—Shock—Epirubicin—urinary bladder cancer	0.000595	0.000802	CcSEcCtD
Lurasidone—Convulsion—Doxorubicin—urinary bladder cancer	0.000594	0.000801	CcSEcCtD
Lurasidone—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000593	0.000799	CcSEcCtD
Lurasidone—Hypertension—Doxorubicin—urinary bladder cancer	0.000591	0.000798	CcSEcCtD
Lurasidone—Tachycardia—Epirubicin—urinary bladder cancer	0.00059	0.000796	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000588	0.000794	CcSEcCtD
Lurasidone—Skin disorder—Epirubicin—urinary bladder cancer	0.000587	0.000792	CcSEcCtD
Lurasidone—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000584	0.000788	CcSEcCtD
Lurasidone—Insomnia—Methotrexate—urinary bladder cancer	0.000584	0.000788	CcSEcCtD
Lurasidone—Myalgia—Doxorubicin—urinary bladder cancer	0.000583	0.000787	CcSEcCtD
Lurasidone—Anxiety—Doxorubicin—urinary bladder cancer	0.000581	0.000784	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000579	0.000781	CcSEcCtD
Lurasidone—Dyspnoea—Methotrexate—urinary bladder cancer	0.000576	0.000777	CcSEcCtD
Lurasidone—Somnolence—Methotrexate—urinary bladder cancer	0.000574	0.000774	CcSEcCtD
Lurasidone—Dry mouth—Doxorubicin—urinary bladder cancer	0.00057	0.000769	CcSEcCtD
Lurasidone—Dyspepsia—Methotrexate—urinary bladder cancer	0.000568	0.000767	CcSEcCtD
Lurasidone—Hypotension—Epirubicin—urinary bladder cancer	0.000565	0.000762	CcSEcCtD
Lurasidone—Decreased appetite—Methotrexate—urinary bladder cancer	0.000561	0.000757	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000557	0.000752	CcSEcCtD
Lurasidone—Fatigue—Methotrexate—urinary bladder cancer	0.000557	0.000751	CcSEcCtD
Lurasidone—Infection—Doxorubicin—urinary bladder cancer	0.000555	0.000749	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000551	0.000743	CcSEcCtD
Lurasidone—Shock—Doxorubicin—urinary bladder cancer	0.00055	0.000742	CcSEcCtD
Lurasidone—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000548	0.00074	CcSEcCtD
Lurasidone—Insomnia—Epirubicin—urinary bladder cancer	0.000547	0.000737	CcSEcCtD
Lurasidone—Tachycardia—Doxorubicin—urinary bladder cancer	0.000546	0.000736	CcSEcCtD
Lurasidone—Skin disorder—Doxorubicin—urinary bladder cancer	0.000543	0.000733	CcSEcCtD
Lurasidone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000541	0.000729	CcSEcCtD
Lurasidone—Dyspnoea—Epirubicin—urinary bladder cancer	0.000539	0.000727	CcSEcCtD
Lurasidone—Somnolence—Epirubicin—urinary bladder cancer	0.000537	0.000725	CcSEcCtD
Lurasidone—Dyspepsia—Epirubicin—urinary bladder cancer	0.000532	0.000718	CcSEcCtD
Lurasidone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000528	0.000712	CcSEcCtD
Lurasidone—Decreased appetite—Epirubicin—urinary bladder cancer	0.000525	0.000709	CcSEcCtD
Lurasidone—Hypotension—Doxorubicin—urinary bladder cancer	0.000522	0.000705	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000522	0.000704	CcSEcCtD
Lurasidone—Fatigue—Epirubicin—urinary bladder cancer	0.000521	0.000703	CcSEcCtD
Lurasidone—Abdominal pain—Methotrexate—urinary bladder cancer	0.00051	0.000689	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000509	0.000687	CcSEcCtD
Lurasidone—Insomnia—Doxorubicin—urinary bladder cancer	0.000506	0.000682	CcSEcCtD
Lurasidone—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000498	0.000672	CcSEcCtD
Lurasidone—Somnolence—Doxorubicin—urinary bladder cancer	0.000497	0.000671	CcSEcCtD
Lurasidone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000494	0.000667	CcSEcCtD
Lurasidone—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000492	0.000664	CcSEcCtD
Lurasidone—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000486	0.000656	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000483	0.000651	CcSEcCtD
Lurasidone—Fatigue—Doxorubicin—urinary bladder cancer	0.000482	0.00065	CcSEcCtD
Lurasidone—Abdominal pain—Epirubicin—urinary bladder cancer	0.000478	0.000644	CcSEcCtD
Lurasidone—Asthenia—Methotrexate—urinary bladder cancer	0.000463	0.000625	CcSEcCtD
Lurasidone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000457	0.000617	CcSEcCtD
Lurasidone—Pruritus—Methotrexate—urinary bladder cancer	0.000457	0.000616	CcSEcCtD
Lurasidone—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000442	0.000596	CcSEcCtD
Lurasidone—Diarrhoea—Methotrexate—urinary bladder cancer	0.000442	0.000596	CcSEcCtD
Lurasidone—Asthenia—Epirubicin—urinary bladder cancer	0.000434	0.000585	CcSEcCtD
Lurasidone—Pruritus—Epirubicin—urinary bladder cancer	0.000428	0.000577	CcSEcCtD
Lurasidone—Dizziness—Methotrexate—urinary bladder cancer	0.000427	0.000576	CcSEcCtD
Lurasidone—Diarrhoea—Epirubicin—urinary bladder cancer	0.000413	0.000558	CcSEcCtD
Lurasidone—Vomiting—Methotrexate—urinary bladder cancer	0.000411	0.000554	CcSEcCtD
Lurasidone—Rash—Methotrexate—urinary bladder cancer	0.000407	0.000549	CcSEcCtD
Lurasidone—Dermatitis—Methotrexate—urinary bladder cancer	0.000407	0.000549	CcSEcCtD
Lurasidone—Asthenia—Doxorubicin—urinary bladder cancer	0.000401	0.000541	CcSEcCtD
Lurasidone—Dizziness—Epirubicin—urinary bladder cancer	0.0004	0.000539	CcSEcCtD
Lurasidone—Pruritus—Doxorubicin—urinary bladder cancer	0.000396	0.000534	CcSEcCtD
Lurasidone—Vomiting—Epirubicin—urinary bladder cancer	0.000384	0.000518	CcSEcCtD
Lurasidone—Nausea—Methotrexate—urinary bladder cancer	0.000384	0.000517	CcSEcCtD
Lurasidone—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000383	0.000516	CcSEcCtD
Lurasidone—Rash—Epirubicin—urinary bladder cancer	0.000381	0.000514	CcSEcCtD
Lurasidone—Dermatitis—Epirubicin—urinary bladder cancer	0.000381	0.000513	CcSEcCtD
Lurasidone—Dizziness—Doxorubicin—urinary bladder cancer	0.00037	0.000499	CcSEcCtD
Lurasidone—Nausea—Epirubicin—urinary bladder cancer	0.000359	0.000484	CcSEcCtD
Lurasidone—Vomiting—Doxorubicin—urinary bladder cancer	0.000355	0.00048	CcSEcCtD
Lurasidone—Rash—Doxorubicin—urinary bladder cancer	0.000353	0.000476	CcSEcCtD
Lurasidone—Dermatitis—Doxorubicin—urinary bladder cancer	0.000352	0.000475	CcSEcCtD
Lurasidone—Nausea—Doxorubicin—urinary bladder cancer	0.000332	0.000448	CcSEcCtD
